Behind the Study: Metronomic Cyclophosphamide – Innate Immunity and Anti-Tumor Responses
February 1, 2021
Researcher Mary Janatpour describes the findings in a paper she helped author in Oncotarget titled, "Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate... read more